Medical Quiz Flashcards
Medications that exacerbate psoriasis
Lithium
Weaning prednisolone
Terbinafine
Hydroxychloroquine
anti TNF
Beta blocker
NSAIDs
Interferon
Iodides
BLASTIN - Beta blockers, Lithium, Anti-malarials / Acei, Steroid withdrawal, Terbinafine / TNFi, Interferon /Infliximab , NSAIDs
Also: PD1, dupilumab
Psoriasis triggers
D SWISH HIPS
Drugs
Stress
Weight gain
Infection - strep, HIV
Smoking
HIV
Hypocalcaemia
Injury (Koebnerisation - sunburn, drug eruption or viral exanthem)
Pregnancy
Steroid wean
Merkel cell carcinoma staging
Stage 0 - in situ
Stage 1 - </= 2cm, negative nodes
Stage 2A - >2cm
Stage 2B - tumour invading bone, muscle, fascia, cartilage
Stage 3 - lymph node positive
Stage 4 - metastasis
Merkel cell carcinoma stains
CK20
Polyomavirus
chromogranin
synaptophysin
neurofilament
Mycosis fungoides staging
1A - Patches and plaques <10%
1B - Patches and plaques >10%
2A - Lymphadenopathy
2B - Tumour
3 - Erythroderma
4 - Visceral, nodal
Hedgehog inhibitor side effects
Teratogenicity - protection 24 months after last dose (8 months for men)
Alopecia
Altered taste
Musculoskeletal pain
CK rise
Muscle spasms
Fatigue
Nausea, vomiting, diarrhoea, abdo pain
Headache
No blood donation at least 20 months
Not in children - premature fusion of epiphyses
Sonidegib - CYP450 3A4
SCAR
+/- QT prolongation
+/- hepatotoxicity
Finasteride and dutasteride
MoA
Side effects
Dose
Finasteride
- Type II 5 alpha reductase inhibitor
- 1mg daily
Dutasteride
- combined type I and type II 5α-reductase inhibitor
- 0.5mg daily
Side effects:
Low libido, erectile dysfunction, gynaecomastia, depression, rare suicidality
Teratogenicity - pregnancy category X
Cutaneous toxicity to acitretin, according to pbs
- Skin peeling hands and feet causing discomfort and pain to prevent daily activities, and not responding to regular and liberal moisturiser
- Skin burning disturbing daily activities and sleep
Psoriasis associations/comorbidities
IBD
Metabolic syndrome, diabetes, dyslipidaemia, HTN, obesity
Atherosclerotic CV disease (MI, CVA, PAD)
NASH/NAFLD
PsA
Mental health/ substance use
Uveitis, conjunctivitis
Psoriasis biologic criteria hands/feet/face
- treated by dermatologist
- 18+
- must have had for 6 months
- must be systemic monotherapy (other than MTX)
- must have failed to achieve adequate response to at least 6 weeks of 2 of the following 6 treatments:
1. Phototherapy - min 3 treatments / week
2. MTx 10mg weekly
3. CsA 2mg/kg/day
4. Acitretin 0.4mg/kg/day
5. Apremilast 30mg BD
6. Deucravacitinib 6mg OD - response must be recorded at the end of the treatment course OR no later than 4/52 post treatment
Surface area 30% or more
OR
Score severe or very severe (3 or 4) for 2 of the subscores erythema, thickness, scaling
Pustular psoriasis types
Generalised:
- von Zumbusch/acute
- exanthematic
- annular
- impetigo herpetiformis
Localised:
- Palmoplantar pustulosis
- acrodermatitis continua of Hallopeau
- parakeratosis pustulosa (single digit)
HLA-CW6
- increased susceptibility for psoriasis in Asian and Middle Eastern populations
- guttate psoriasis
- early onset psoriasis
- PsA
5 types of psoriatic arthritis
- DIPs
- Asymmetric oligoarthritis
- Symmetric polyarthritis
- Arthritis mutilans
- Spondylitis and sacroiliitis
Clinical variants of psoriasis
CPP
Guttate
Erythrodermic
Pustular (and variants)
Rupoid
Special sites: flexural, scalp, genital, nail, palmoplantar, oral (annulus migrans, looks like geographic tonngue)
Psoriasis histopath
Hyper and parakeratosis
Hypogranulosis
Acanthosis
Elongated rete ridges
Increased vascularity dermal papillae
Neutrophils
Micro-abscesses of Munro (accumulation of neuts in stratum corneum)
Spongiform pustule of Kogoj (neuts within spongiotic pustule)
nbUVB starting doses
Same for psoriasis, eczema and vitiligo
SPT 1-2 = 100mJ/cm^3
SPT 3-4 = 200mJ/cm^3
SPT 5-6 = 300mJ/cm^3
Dose increments for nbUVB
Linear increments of 50-100mJ/cm^3 per visit for all skin types
OR
20% for psoriasis and vitiligo; and 15% for eczema
Maximum nbUVB dosage
For eczema:
SPT 1-2 = 1500mJ/cm^3
SPT 3-4 = 2500mJ/cm^3
SPT 5-6 = 3500mJ/cm^3
For psoriasis and vitiligo:
SPT 1-2 = 2000mJ/cm^3
SPT 3-4 = 3000mJ/cm^3
SPT 5-6 = 4000mJ/cm^3
Expected effect from nbUVB for psoriasis
60-75% of patients achieve PASI 75 at week 12
When to assess nbUVB outcomes
Eczema and psoriasis - after 18-24 sessions, then every 24-36 sessions
Vitiligo - every 36 sessions
nbUVB max doses for
Hands and feet
Face
Body
Body
SPT 1-2 = 2000mJ/cm^3
SPT 3-4 = 3000mJ/cm^3
SPT 5-6 = 4000mJ/cm^3
Hands and feet
SPT 1-2 = 3000mJ/cm^3
SPT 3-4 = 4000mJ/cm^3
SPT 5-6 = 5000mJ/cm^3
Face
SPT 1-2 = 1000mJ/cm^3
SPT 3-4 = 2000mJ/cm^3
SPT 5-6 = 3000mJ/cm^3
How to handle missed nbUVB sessions
1 week - HOLD at previous dose (unless burns)
2 weeks - reduce dose by 25%
3 weeks - reduce dose by 50%
4 weeks - review and restart
IL17s pros and cons
And list
Pros:
- PsA and psoriasis efficacy
Cons:
- Not in IBD
- ISRs
IL23s pros and cons
And list
Pros:
- Fewer injections
- Efficacious for psoriasis
- Efficacy in psoriatic arthritis also increasingly acknowledged (guselkumab, risankizumab, ustekinumab)
- With ustekinumab - weight based dose so if they are larger they have access to a greater dose (if >101kg)
Cons: